Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Medical Center
mi
from
Des Moines, IA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Jewish Hospital & St. Mary's Healthcare
mi
from
Louisville, KY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Jewish Hospital & St. Mary's Healthcare
mi
from
Louisville, KY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Cardiovascular Research, LLC
mi
from
Shreveport, LA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Cardiovascular Research, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Maine Medical Center
mi
from
Portland, ME
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Union Memorial Hospital
mi
from
Baltimore, MD
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Union Memorial Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
HealthEast St. Joseph's Hospital
mi
from
Saint Paul, MN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
HealthEast St. Joseph's Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital of Kansas City
mi
from
Kansas City, MO
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital of Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Cox Medical Centers
mi
from
Springfield, MO
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Cox Medical Centers
mi
from
Springfield, MO
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Deborah Heart and Lung Center
mi
from
Browns Mills, NJ
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Deborah Heart and Lung Center
mi
from
Browns Mills, NJ
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Morristown Memorial Hospital
mi
from
Morristown, NJ
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Morristown Memorial Hospital
mi
from
Morristown, NJ
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Presbyterian Hospital
mi
from
Albuquerque, NM
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
New York Univ. Medical Center
mi
from
New York, NY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital Health Center
mi
from
Syracuse, NY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital Health Center
mi
from
Syracuse, NY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center
mi
from
Charlotte, NC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Wake Medical Center
mi
from
Raleigh, NC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Wake Medical Center
mi
from
Raleigh, NC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
mi
from
Cincinnati, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
OhioHealth Research and Innovation Institute - Riverside Methodist Hospital
mi
from
Columbus, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
OhioHealth Research and Innovation Institute - Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Mercy St. Vincent Medical Center
mi
from
Toledo, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Mercy St. Vincent Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Integris Baptist Medical Center
mi
from
Oklahoma City, OK
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Integris Baptist Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Oklahoma Heart Hospital
mi
from
Oklahoma City, OK
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Oklahoma Heart Hospital
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Lankenau Medical Center
mi
from
Wynnewood, PA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Lankenau Medical Center
mi
from
Wynnewood, PA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Sisters of Charity Providence Hospital
mi
from
Columbia, SC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Sisters of Charity Providence Hospital
mi
from
Columbia, SC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University Medical Center-Greenville Memorial Hospital
mi
from
Greenville, SC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University Medical Center-Greenville Memorial Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Grand Strand Regional Medical Center
mi
from
Myrtle Beach, SC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Grand Strand Regional Medical Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Jackson Madison County General Hospital
mi
from
Jackson, TN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Jackson Madison County General Hospital
mi
from
Jackson, TN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Centennial Medical Center
mi
from
Nashville, TN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Centennial Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Baylor Heart and Vascular Hospital
mi
from
Dallas, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Baylor Heart and Vascular Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. Luke's Episcopal Hospital
mi
from
Houston, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
The Heart Hospital Baylor Plano
mi
from
Plano, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
The Heart Hospital Baylor Plano
mi
from
Plano, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. David's Round Rock Medical Center
mi
from
Round Rock, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. David's Round Rock Medical Center
mi
from
Round Rock, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University of Vermont Medical Center
mi
from
Burlington, VT
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Charleston Area Medical Center
mi
from
Charleston, WV
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Charleston Area Medical Center
mi
from
Charleston, WV
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Instituto do Coração (InCor)
mi
from
Sao Paulo,
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Instituto do Coração (InCor)
mi
from
Sao Paulo,
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Research Alliance - Lutheran Hospital
mi
from
Fort Wayne, IN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Research Alliance - Lutheran Hospital
mi
from
Fort Wayne, IN
Click here to add this to my saved trials